YU79092A - Direktno molekularno klonirnje modofikovanog eukariotičnog citoplazmatičnog dnk virusnog genoma - Google Patents
Direktno molekularno klonirnje modofikovanog eukariotičnog citoplazmatičnog dnk virusnog genomaInfo
- Publication number
- YU79092A YU79092A YU79092A YU79092A YU79092A YU 79092 A YU79092 A YU 79092A YU 79092 A YU79092 A YU 79092A YU 79092 A YU79092 A YU 79092A YU 79092 A YU79092 A YU 79092A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- modified
- dna
- dna molecule
- molecular cloning
- viral genome
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title abstract 6
- 238000010369 molecular cloning Methods 0.000 title abstract 3
- 108020004414 DNA Proteins 0.000 abstract 10
- 102000053602 DNA Human genes 0.000 abstract 5
- 241000700647 Variola virus Species 0.000 abstract 4
- 230000001086 cytosolic effect Effects 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 3
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000002458 infectious effect Effects 0.000 abstract 2
- 210000002845 virion Anatomy 0.000 abstract 2
- 208000001203 Smallpox Diseases 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 108091008146 restriction endonucleases Proteins 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
otkriven je postupak za proizvodnju jednog modifikovanog eukariotičnog citoplazmatičnog DNK virusa direktnim molekularnim kloniranjem nekog modifikovanog DNK molekula koji uključuje jedan modifikovani citoplazmatični DNK virusni genom. Pronadjeni postupak uključuje stupnjeve: (I) modifikovanje pod vanćelijskim uslovima jednog DNK molekula koji uključuje jedan prvi citoplazmatični DNK virusni genom, da bi proizveo jedan modifiko van DNK molekul koji obuh-vata modifikovani citoplazmatični DNK virusni genom; (II) uvod-jenje modifikovanog DNK molekula u jednu prvu ćeliju domaćina, gde se pakuje modifikovani DNK molekul u infektivne virione; i (III) ponovno dobijanje iz ćelije domaćina, viriona koji su sastavljeni od modifikovanog virusnog genoma. Ćelija domaćina inficirana je sa jednim pomoćnim virusom koji je odredjen da pakuje modifikovane virusne genome u infektivne virone. Opisani su primeri pakovanja jednog modifikovanog genoma virusa izazivača boginja, pomoću nekog pomoćnog virusa izazivača boginja, istog ili različitog roda. Otkriveni su, takodje, novi vektori virusa izazivača boginja za direktno molekularno kloniranje otvorenih ok vira za čitanje, u jedno mesto raskidanja za neki restrikcioni enzim, koje je jedinstveno u vektoru. U jednom model - vektoru virusa izazivača boginja otvoreni okvir za čitanje transkribovan je pomoću jednog promotora lociranog u vektorskoj DNK uzvodno od jednog višestrukog mesta za kloniranje, koje se sastoji od nekoliko jedinstvenih mesta ras-kidanja.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/750,080 US5445953A (en) | 1991-08-26 | 1991-08-26 | Direct molecular cloning of a modified poxvirus genome |
US91473892A | 1992-07-20 | 1992-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU79092A true YU79092A (sh) | 1995-12-04 |
Family
ID=27115227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU79092A YU79092A (sh) | 1991-08-26 | 1992-08-25 | Direktno molekularno klonirnje modofikovanog eukariotičnog citoplazmatičnog dnk virusnog genoma |
Country Status (17)
Country | Link |
---|---|
US (2) | US6265183B1 (sh) |
EP (1) | EP0561034B1 (sh) |
JP (1) | JPH06261763A (sh) |
AT (1) | ATE181108T1 (sh) |
AU (1) | AU652467B2 (sh) |
BR (1) | BR9203322A (sh) |
CA (1) | CA2076839C (sh) |
CZ (1) | CZ264192A3 (sh) |
DE (1) | DE69229390T2 (sh) |
FI (1) | FI111384B (sh) |
HU (1) | HU219369B (sh) |
MX (1) | MX9204926A (sh) |
NO (1) | NO310306B1 (sh) |
PL (1) | PL295733A1 (sh) |
SI (1) | SI9200190A (sh) |
SK (1) | SK264192A3 (sh) |
YU (1) | YU79092A (sh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
EP0753581A1 (en) | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
AU5446700A (en) * | 1999-05-28 | 2000-12-18 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
US20040063653A1 (en) * | 2000-12-21 | 2004-04-01 | Shiver John W. | Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol |
US8623379B2 (en) * | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
EP2388015A1 (en) | 2000-03-02 | 2011-11-23 | Emory University | DNA expression vectors and methods of use |
EP1372710B1 (en) * | 2001-03-08 | 2009-10-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mva expressing modified hiv envelope, gag, and pol genes |
US7223740B2 (en) | 2001-05-23 | 2007-05-29 | Fornix Biosciences N.V. | Vectors for enhanced expression of VEGF for atrial disease treatment |
WO2002095038A2 (en) * | 2001-05-23 | 2002-11-28 | Fornix Biosciences N.V. | Vectors for enhanced expression of vegf for disease treatment |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
AU2002347317B2 (en) * | 2001-11-30 | 2008-06-26 | Isis Innovation Limited | Vaccine |
GB2382578A (en) * | 2001-11-30 | 2003-06-04 | Isis Innovation | Fowlpox-based vaccine |
AU2003203527A1 (en) * | 2002-04-12 | 2003-10-30 | Sumitomo Electric Industries, Ltd. | Control of the ratio of lap to lip |
EA012160B1 (ru) * | 2002-05-16 | 2009-08-28 | Бавариан Нордик А/С | Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном, и его применение |
GB0215621D0 (en) * | 2002-07-05 | 2002-08-14 | Imp College Innovations Ltd | Improved poxvirus vaccines |
US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
US20090098529A1 (en) * | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
CN114262690A (zh) | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
WO2014127825A1 (en) | 2013-02-21 | 2014-08-28 | Boehringer Ingelheim Vetmedica Gmbh | H5 proteins of h5n1 influenza virus for use as a medicament |
US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
BR102015012334A2 (pt) * | 2015-05-27 | 2016-11-29 | Fundação Hemoct De Ribeirão Preto Fundherp | processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea |
CN116064669A (zh) | 2016-01-08 | 2023-05-05 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
WO2024011250A1 (en) | 2022-07-08 | 2024-01-11 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5155020A (en) | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5135855A (en) * | 1986-09-03 | 1992-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
US5266313A (en) | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
FR2619314B1 (fr) * | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
NL9020389A (nl) | 1989-03-08 | 1991-12-02 | Health Research Inc | Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen. |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
JP2549224B2 (ja) * | 1990-01-26 | 1996-10-30 | イムノ・アクチェンゲゼルシャフト | 組換えにより産生される血液因子及びその血液因子の発現方法並びにその方法に使用されるワクシニアウイルス組換え体 |
US5204243A (en) | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
EP0953648A3 (en) | 1990-09-25 | 2007-09-12 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
US5863542A (en) | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
US5989561A (en) | 1991-03-07 | 1999-11-23 | Virogenetics Corporation | Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
AU4560693A (en) | 1992-07-30 | 1994-03-03 | Akzo Nobel N.V. | Non-shedding live herpesvirus vaccine |
EP0805854A4 (en) | 1995-01-13 | 2000-06-07 | Virogenetics Corp | IMMUNOGENIC COMPOSITIONS WHICH RECOMBINANT CONTAINED WEAKENED POX VIRUSES THAT EXPECT AN HTLV ANTIQUE |
-
1992
- 1992-08-11 EP EP92113675A patent/EP0561034B1/en not_active Expired - Lifetime
- 1992-08-11 DE DE69229390T patent/DE69229390T2/de not_active Expired - Lifetime
- 1992-08-11 AT AT92113675T patent/ATE181108T1/de not_active IP Right Cessation
- 1992-08-25 AU AU21269/92A patent/AU652467B2/en not_active Ceased
- 1992-08-25 HU HU9202737A patent/HU219369B/hu not_active IP Right Cessation
- 1992-08-25 YU YU79092A patent/YU79092A/sh unknown
- 1992-08-25 CA CA002076839A patent/CA2076839C/en not_active Expired - Fee Related
- 1992-08-25 NO NO19923323A patent/NO310306B1/no not_active IP Right Cessation
- 1992-08-26 SI SI19929200190A patent/SI9200190A/sl unknown
- 1992-08-26 MX MX9204926A patent/MX9204926A/es unknown
- 1992-08-26 FI FI923828A patent/FI111384B/fi active
- 1992-08-26 CZ CS922641A patent/CZ264192A3/cs unknown
- 1992-08-26 JP JP4250826A patent/JPH06261763A/ja active Pending
- 1992-08-26 SK SK2641-92A patent/SK264192A3/sk unknown
- 1992-08-26 PL PL29573392A patent/PL295733A1/xx unknown
- 1992-08-26 BR BR929203322A patent/BR9203322A/pt not_active Application Discontinuation
-
1994
- 1994-12-19 US US08/358,928 patent/US6265183B1/en not_active Expired - Fee Related
-
1996
- 1996-05-22 US US08/651,472 patent/US6103244A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE181108T1 (de) | 1999-06-15 |
NO923323D0 (no) | 1992-08-25 |
EP0561034A2 (en) | 1993-09-22 |
US6265183B1 (en) | 2001-07-24 |
CZ264192A3 (en) | 1993-08-11 |
FI923828A (fi) | 1993-02-27 |
SI9200190A (en) | 1993-03-31 |
SK264192A3 (en) | 1995-08-09 |
DE69229390T2 (de) | 1999-11-11 |
MX9204926A (es) | 1994-02-28 |
NO310306B1 (no) | 2001-06-18 |
JPH06261763A (ja) | 1994-09-20 |
EP0561034A3 (sh) | 1995-04-26 |
PL295733A1 (en) | 1993-05-17 |
DE69229390D1 (de) | 1999-07-15 |
NO923323L (no) | 1993-03-01 |
AU2126992A (en) | 1993-03-04 |
CA2076839A1 (en) | 1993-02-27 |
EP0561034B1 (en) | 1999-06-09 |
CA2076839C (en) | 2007-06-12 |
AU652467B2 (en) | 1994-08-25 |
US6103244A (en) | 2000-08-15 |
BR9203322A (pt) | 1993-03-30 |
FI923828A0 (fi) | 1992-08-26 |
HUT69927A (en) | 1995-09-28 |
HU219369B (en) | 2001-03-28 |
FI111384B (fi) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU79092A (sh) | Direktno molekularno klonirnje modofikovanog eukariotičnog citoplazmatičnog dnk virusnog genoma | |
Bredenbeek et al. | Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs | |
Davis et al. | Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1 | |
US7572453B2 (en) | Chimeric alphavirus replicon particles | |
CA2233932C (en) | Vaccines against infections caused by yf virus; yf infectious cdna, method for producing a recombinant yf virus from the yf infectious cdna and plasmids to assemble the yf infectious cdna | |
CN1989250A (zh) | Tc-83衍生的甲病毒属载体、颗粒和方法 | |
UA84254C2 (ru) | МИНИМАЛЬНАЯ ПЛАЗМИДНАЯ СИСТЕМА ДЛЯ ГЕНЕРИРОВАНИЯ ИНФЕКЦИОННЫХ МИНУС-ЦЕПОЧЕЧНЫХ РНК ВИРУСОВ С КЛОНИРОВАННОЙ ВИРУСНОЙ кДНК, КЛЕТКА-ХОЗЯИН, КОТОРАЯ ВКЛЮЧАЕТ ПЛАЗМИДНУЮ СИСТЕМУ, СПОСОБ ПРОДУЦИРОВАНИЯ ИНФЕКЦИОННОГО МИНУС-ЦЕПОЧЕЧНОГО РНК ВИРУСА И СПОСОБ ПРИВИВКИ СУБЪЕКТА ОТ ИНФЕКЦИИ МИНУС-ЦЕПОЧЕЧНОГО РНК ВИРУСА | |
ATE454039T1 (de) | Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung | |
Ferreira et al. | Weak bases affect late stages of Mayaro virus replication cycle in vertebrate cells | |
Manrique et al. | Mutational analysis of the feline immunodeficiency virus matrix protein | |
JP2006526393A5 (sh) | ||
Inocencio et al. | A mutant CHO-K1 strain with resistance to Pseudomonas exotoxin A is unable to process the precursor fusion glycoprotein of Newcastle disease virus | |
Shen et al. | Towards construction of viral vectors based on avian coronavirus infectious bronchitis virus for gene delivery and vaccine development | |
DE602004013165D1 (de) | Chimärisches vektorsystem | |
CA2515166A1 (en) | Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome | |
Du et al. | An in vitro recombination-based reverse genetic system for rapid mutagenesis of structural genes of the Japanese encephalitis virus | |
CA2558864A1 (en) | Direct molecular cloning of a modified eukaryotic cytoplasmic dna virus genome | |
EP4375368A1 (en) | Recombinant virus containing degron, preparation method therefor, and application thereof | |
Reiss et al. | Newly synthesized class II MHC chains are required for VSV G presentation to CTL clones | |
ATE342999T1 (de) | Auf siv basierende verpackungsdefiziente vektoren | |
JPH0692996A (ja) | C型肝炎ウィルス粒子を構成する蛋白質およびその発現 | |
Liljeström | Recombinant self-replicating RNA vaccines | |
Beasleyb et al. | Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs | |
Hoover et al. | Generation of West Nile Virus Infectious Clones Containing Amino Acid Insertions Between Capsid and Capsid Anchor. |